Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001224233 | SCV001396417 | likely benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2023-05-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002393547 | SCV002697799 | uncertain significance | Cardiovascular phenotype | 2022-04-09 | criteria provided, single submitter | clinical testing | The p.S469L variant (also known as c.1406C>T), located in coding exon 8 of the FLNC gene, results from a C to T substitution at nucleotide position 1406. The serine at codon 469 is replaced by leucine, an amino acid with dissimilar properties. This variant was reported in an unaffected control subject from a hypertrophic cardiomyopathy (HCM) study (Cui H et al. Mol Genet Genomic Med, 2018 11;6:1104-1113). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |